X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Position Boosted by Barclays PLC

Barclays PLC boosted its position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 196.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 277,682 shares of the company’s stock after buying an additional 183,861 shares during the quarter. Barclays PLC owned approximately 0.16% of X4 Pharmaceuticals worth $185,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. XTX Topco Ltd raised its holdings in shares of X4 Pharmaceuticals by 41.7% during the third quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after purchasing an additional 46,397 shares during the period. Jane Street Group LLC lifted its position in X4 Pharmaceuticals by 103.4% in the third quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after purchasing an additional 126,296 shares during the period. State Street Corp lifted its holdings in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after acquiring an additional 189,105 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of X4 Pharmaceuticals by 15.1% during the third quarter. Point72 Asset Management L.P. now owns 625,052 shares of the company’s stock worth $418,000 after purchasing an additional 81,968 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $30,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on XFOR. HC Wainwright decreased their price target on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating for the company in a report on Thursday, November 14th. Stifel Nicolaus dropped their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 5.1 %

X4 Pharmaceuticals stock opened at $0.70 on Wednesday. The firm’s fifty day simple moving average is $0.54 and its 200-day simple moving average is $0.63. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals, Inc. has a 1-year low of $0.26 and a 1-year high of $1.60. The company has a market capitalization of $119.72 million, a P/E ratio of -7.80 and a beta of 0.14.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.